Target intelligence / Profile preview

Forkhead box P3 (FOXP3)

Target
FOXP3
Molecular classification
Transcription factor, Forkhead box family
01

Overview

Forkhead box P3 (FOXP3) is a transcription factor that serves as the master regulator for the development and inhibitory function of regulatory T cells (Tregs) [UniProt, Hori et al., 2003]. It belongs to the forkhead/winged-helix family and is primarily expressed in a subset of CD4+ T cells, where it controls the expression of genes essential for immune suppression, such as IL-10 and CTLA-4 [NCBI Gene, Togashi et al., 2019]. FOXP3 is critical for maintaining peripheral tolerance; its deficiency or mutation leads to the development of IPEX syndrome, a severe multi-organ autoimmune disease [StatPearls]. In oncology, FOXP3+ Tregs are often recruited to the tumor microenvironment, where they facilitate immune evasion by inhibiting the activity of cytotoxic T cells and natural killer cells [Togashi et al., 2019]. Consequently, FOXP3 and the cells expressing it are major targets for therapeutic intervention, with strategies focusing on depleting Tregs in cancer or expanding/stabilizing them in autoimmune and inflammatory conditions [Hori et al., 2003; Togashi et al., 2019; Klatzmann & Abbas, 2015].

Other names
ScurfinIPEXForkhead box protein P3SCJFJM2Regulatory T cellsTregsFOXP3-positive regulatory T cells
02

Mechanism of action

Modulation of regulatory T cell (Treg) development and suppressive function through transcriptional regulation of immune-related genes, or direct depletion/expansion of FOXP3-expressing cell populations [Hori et al., 2003; Togashi et al., 2019; Klatzmann & Abbas, 2015].

03

Biological functions

Immune responseImmune toleranceGene expression regulationT cell differentiation
04

Disease associations

CancerAutoimmune diseaseInflammationInfection
05

Safety considerations

Systemic autoimmunity [StatPearls]Immune-related adverse events (irAEs) [Togashi et al., 2019]Increased susceptibility to infections [Togashi et al., 2019]Potential for tumor hyper-progression [Togashi et al., 2019]
06

Interacting drugs

Aldesleukin [Klatzmann & Abbas, 2015]

7 more in the full profile.

07

Biomarkers

FOXP3 expression [UniProt]CD4+CD25+CD127low phenotype [Liu et al., 2006]Treg-specific demethylated region (TSDR) methylation status [Baron et al., 2007]

Beyond the preview

Go deeper on Forkhead box P3 (FOXP3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forkhead box P3 (FOXP3).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call